Aimee D. Shu, MD

Chief Medical Officer
Ascendis Pharma, Inc
Palo Alto, California, United States

Disclosure information not submitted.

Presentation(s):

• ORF16-07 - Palopegteriparatide Treatment in Adults with Hypoparathyroidism: Final Results of the Phase 3 PaTHway Trial

  Saturday, June 13, 2026
  2:45 PM - 3:00 PM CT

• SUN-770 - Palopegteriparatide Enhances Work Functioning and Productivity in Employed Adults with Chronic Hypoparathyroidism: 156-Week Results from the Pathway Trial

  Sunday, June 14, 2026
  9:00 AM - 4:00 PM CT